The impact of the C-Terminal domain on the interaction of human DNA topoisomerase II α and β with DNA

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Gilroy, Kathryn L ^a,b   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE II BETA; MAGNESIUM ION; MANGANESE; UNCLASSIFIED DRUG; DNA; DNA BINDING PROTEIN; ION; METAL; MUTANT PROTEIN; TUMOR ANTIGEN;

ANISOTROPY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME SUBSTRATE COMPLEX; FLUORESCENCE ANALYSIS; GENE FUNCTION; IN VIVO STUDY; INTERACTIONS WITH DNA; PROTEIN DNA BINDING; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECT; FLUORESCENCE POLARIZATION; GENETICS; HUMAN; METABOLISM; OSMOLARITY; PHYSIOLOGY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; SACCHAROMYCES CEREVISIAE;

ANTIGENS, NEOPLASM; DNA; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FLUORESCENCE POLARIZATION; HUMANS; IONS; METALS; MODELS, BIOLOGICAL; MUTANT PROTEINS; OSMOLAR CONCENTRATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SACCHAROMYCES CEREVISIAE;

EID: 79951921354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014693     Document Type: Article

References (42)

1. Wang JC, (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 3: 430-440.
2. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, et al. (2006) A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science 312: 1798-1802.
3. Kitagawa H, Fujiki R, Yoshimura K, Mezaki Y, Uematsu Y, et al. (2003) The chromatin-remodelling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 113: 905-917.
4. Ju BG, Solum D, Song EJ, Lee K-J, Rose DW, et al. (2004) Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMKinaseIIdelta-dependent neurogenic gene activation pathway. Cell 119: 815-829.
5. Austin CA, Marsh KL, (1998) Eukaryotic DNA topoisomerase IIβ. Bioessays 20: 215-226.
6. McNamara S, Wang H, Hanna N, Miller WH Jr, (2008) Topoisomerase IIβ negatively modulates retinoic acid receptor alpha function: A novel mechanism of retinoic acid resistance. Mol Cell Biol 28: 2066-2077.
7. Sano K, Miyaji-Yamaguchi M, Tsutsui KM, Tsutsui K, (2008) Topoisomerase IIβ activates a subset of neuronal genes that are repressed in AT-rich genomic environment. PLoS One 3: e4103.
8. Corbett KD, Berger JM, (2004) Structure, molecular mechanisms and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 33: 95-118.
9. Li W, Wang JC, (1997) Footprinting of Yeast DNA Topoisomerase II Lysyl Side Chains Involved in Substrate Binding and Interdomainal Interactions. J Biol Chem 272: 31190-31195.
10. Berger JM, Gamblin SJ, Harrison SC, Wang JC, (1996) Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232.
11. Grishin NV, (2000) Two tricks in one bundle: Helix-turn-helix gains enzymatic activity. Nucleic Acids Res 28: 2229-2233.
12. Morant-Lhomel A, Rene B, Zargarian L, Troalen F, Mauffret O, et al. (2006) Self association and DNA binding properties of the human topoisomerase IIA α2HTH module. Biochimie 99: 253-263.
13. Dong KC, Berger JM, (2007) Structural basis for gate-DNA recognition and bending by type IIA topoisomerases. Nature 450: 1201-1205.
14. Wigley DB, Davies GJ, Dodson EJ, Maxwell A, Dodson G, (1991) Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 351: 624-629.
15. Noble CG, Maxwell A, (2002) The role of GyrB in the DNA Cleavage-religation reaction of DNA gyrase: A proposed two metal ion mechanism. J Mol Biol 318: 361-371.
16. Osheroff N, (1987) Role of the divalent cation in topoisomerase II mediated reactions. Biochemistry 26: 6402-6406.
17. Aravind L, Leipe DD, Koonin EV, (1998) Toprim - a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res 26: 4205-4213.
18. West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R, et al. (2000) Mutagenesis of E477 or K505 in the B' domain of Human Topoisomerase IIβ Increases the requirement for Magnesium ions during strand passage. Biochemistry 39: 1223-1233.
19. Leontiou C, Lakey JH, Lightowlers R, Turnbull RM, Austin CA, (2006) Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance. Mol Pharmacol 69: 130-139.
20. Schmidt BH, Burgin AB, Deweese JE, Osheroff N, Berger JM, (2010) A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature 465: 641-645.
21. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, et al. (2010) Type IIA topoisomerase II inhibition by a new class of antibacterial agents. Nature 466: 935-940.
22. Laponogov I, Pan XS, Veselkov DA, McAuley KE, Fisher LM, et al. (2010) Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5: e11338.
23. Deweese JE, Burch AM, Burgin AB, Osheroff N, (2009) Use of divalent metal ions in the DNA cleavage reaction of human type II topoisomerases. Biochemistry 48: 1862-1869.
24. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, et al. (2010) Structural basis for quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17: 1152-1153.
25. Leontiou C, Lakey JH, Austin CA, (2004) Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4′-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4′-(9-acridinylamino)-3-methoxy-phenyl)methane sulfonamide but hypersensitivity to etoposide. Mol Pharmacol 66: 430-439.
26. Zechiedrich EL, Osheroff N, (1990) Eukaryotic topoisomerases recognise nucleic acid topology by preferentially interacting with DNA crossovers. The EMBO J 9: 4555-4562.
27. Roca J, Berger JM, Wang JC, (1993) On the simultaneous binding of eukaryotic DNA topoisomerase II to a pair of double-stranded DNA helices. J Biol Chem 268: 14250-14255.
28. Timsit Y, Duplantier B, Jannink G, Sikorav J-L, (1998) Symmetry and Chirality in Topoisomerase II-DNA Crossover Recognition. J Mol Biol 284: 1289-1299.
29. Drake FH, Hofmann GA, Bartus HF, Matttern MR, Crooke ST, et al. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154-8160.
30. McClendon AK, Rodriguez AC, Osheroff N, (2005) Human topoisomerase IIα rapidly relaxes positively supercoiled DNA: Implications for enzyme action ahead of replication forks. J Biol Chem 280: 39337-39345.
31. McClendon AK, Gentry AC, Dickey JS, Brinch M, Bendsen S, et al. (2008) Bimodal recognition of DNA geometry by human topoisomerase Iα: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain. Biochemistry 47: 13169-13178.
32. McClendon AK, Dickey JS, Osheroff N, (2006) Ability of Viral Topoisomerase II to Discern the Handedness of Supercoiled DNA: Bimodal Recognition of DNA Geometry by Type II Enzymes. Biochemistry 45: 11674-11680.
33. Meczes EL, Gilroy KL, West KL, Austin CA, (2008) The impact of the human DNA topoisomerase II C-terminal domain on activity. PLoS One 3: e1754.
34. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, et al. (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 270: 15739-15746.
35. Gilroy KL, Leontiou C, Padget K, Lakey JH, Austin CA, (2006) mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity. Nucleic Acids Res 34: 1597-1607.
36. Wasserman RA, Austin CA, Fisher LM, Wang JC, (1993) Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional, recombinant human DNA topoisomerase IIα in yeast. Cancer Res 53: 3591-3596.
37. Meczes EL, Marsh KL, Fisher LM, Rogers MP, Austin CA, (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2beta construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 39: 367-375.
38. Leontiou C, Watters GP, Gilroy KL, Heslop P, Cowell IG, et al. (2007) Differential selection of acridine resistance mutations in human DNA topoisomerase IIβ is dependent on the acridine structure. Mol Pharmacol 71: 1006-1014.
39. West KL, Austin CA, (1999) Human DNA topoisomerase IIβ binds and cleaves four-way junction DNA in vitro. Nucleic Acids Res 27: 984-992.
40. Leontiou C, Lightowlers R, Lakey JH, Austin CA, (2003) Kinetic analysis of human topoisomerase IIα and β DNA binding by surface plasmon resonance. FEBS Letters 554: 206-210.
41. Baldwin EL, Byl JA, Osheroff N, (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells. Biochemistry 43: 728-735.
42. Bist P, Rao DN, (2003) Identification and mutational analysis of Mg2+ binding site in EcoP15I DNA methyltransferase: Involvement in target base eversion. J Biol Chem 278: 41837-41848.